A study performed by Purcell et al. has shown that CTC load, PD-L1 expression, and gene expression profiles are valuable biomarkers to monitor and predict patient outcomes in stage III NSCLC [432]. This evidence concerns the gene CD274 and non-small cell lung carcinoma.